170 related articles for article (PubMed ID: 13680264)
21. The effects of hormone replacement therapy and resistance training on spine bone mineral density in early postmenopausal women.
Maddalozzo GF; Widrick JJ; Cardinal BJ; Winters-Stone KM; Hoffman MA; Snow CM
Bone; 2007 May; 40(5):1244-51. PubMed ID: 17291843
[TBL] [Abstract][Full Text] [Related]
22. Endocrine analysis of childhood monorchism.
Palmer LS; Gill B; Kogan SJ
J Urol; 1997 Aug; 158(2):594-6. PubMed ID: 9224372
[TBL] [Abstract][Full Text] [Related]
23. The effect of estrogen replacement therapy on plasma serotonin and catecholamines of postmenopausal women.
Blum I; Vered Y; Lifshitz A; Harel D; Blum M; Nordenberg Y; Harsat A; Sulkes J; Gabbay U; Graff E
Isr J Med Sci; 1996 Dec; 32(12):1158-62. PubMed ID: 9007144
[TBL] [Abstract][Full Text] [Related]
24. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
[TBL] [Abstract][Full Text] [Related]
25. Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy.
Maffei S; Mercuri A; Prontera C; Zucchelli GC; Vassalle C
Climacteric; 2006 Dec; 9(6):452-8. PubMed ID: 17085378
[TBL] [Abstract][Full Text] [Related]
26. Biological effects of hormone replacement therapy in relation to serum estradiol levels.
Yasui T; Uemura H; Tezuka M; Yamada M; Irahara M; Miura M; Aono T
Horm Res; 2001; 56(1-2):38-44. PubMed ID: 11815726
[TBL] [Abstract][Full Text] [Related]
27. Estrogen replacement therapy in a man with congenital aromatase deficiency: effects of different doses of transdermal estradiol on bone mineral density and hormonal parameters.
Rochira V; Faustini-Fustini M; Balestrieri A; Carani C
J Clin Endocrinol Metab; 2000 May; 85(5):1841-5. PubMed ID: 10843162
[TBL] [Abstract][Full Text] [Related]
28. [Usefulness of the relationship between follicular stimulating hormone, deoxypyridinoline, estradiol, and inhibin as decision criterion for starting replacement hormone therapy in climacteric and its correlation with symptomatology].
Carranza Lira S; Cortés Fuentes E; González Legorreta SL
Ginecol Obstet Mex; 2000 Jun; 68():242-8. PubMed ID: 10939192
[TBL] [Abstract][Full Text] [Related]
29. Estradiol and follicle-stimulating hormone levels in oophorectomized women using vaginal estrogen.
Taechakraichana N; Intraragsakul A; Panyakhamlerd K; Numchaisrika P; Limpaphayom K
J Med Assoc Thai; 1997 Oct; 80(10):626-30. PubMed ID: 10904564
[TBL] [Abstract][Full Text] [Related]
30. Polymorphisms in the CYP19 and AR genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study.
Tofteng CL; Kindmark A; Brändström H; Abrahamsen B; Petersen S; Stiger F; Stilgren LS; Jensen JE; Vestergaard P; Langdahl BL; Mosekilde L;
Calcif Tissue Int; 2004 Jan; 74(1):25-34. PubMed ID: 14517714
[TBL] [Abstract][Full Text] [Related]
31. Endometrial response to a cyclic regimen of percutaneous 17beta-estradiol and low-dose vaginal micronized progesterone in women with mild-to-moderate hypertension.
Vilodre LC; Osório Wender MC; Sisson de Castro JA; dos Reis FM; Ruschel S; Magalhães JA; Spritzer PM
Gynecol Endocrinol; 2003 Aug; 17(4):323-8. PubMed ID: 14503977
[TBL] [Abstract][Full Text] [Related]
32. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
Brodowska A
Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
[TBL] [Abstract][Full Text] [Related]
33. Hormonal replacement therapy in women with Turner's syndrome in Poland: Analysis of 176 cases.
Wacław J; Irzyniec TJ
Gynecol Endocrinol; 2009 Aug; 25(8):546-50. PubMed ID: 19544120
[TBL] [Abstract][Full Text] [Related]
34. [Relationship of age-related levels of serum sex hormones with bone mineral density decreasing rate in women].
Wang DD; Wu XY; Liao EY; Xie H; Zhang H; Luo XH; Sheng ZF; Peng YQ; Yao XH; Wu XP
Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(30):2359-63. PubMed ID: 24300202
[TBL] [Abstract][Full Text] [Related]
35. [Effects of gonadotropin releasing hormone analogues on chemotherapy-induced ovarian function damage in rats].
Peng P; Yang DZ; Zheng CY; Mo YQ; He YM; Zhang QX
Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):546-50. PubMed ID: 17983495
[TBL] [Abstract][Full Text] [Related]
36. In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender.
Zgliczynski W; Kochman M; Misiorowski W; Zdunowski P
Neuro Endocrinol Lett; 2007 Oct; 28(5):621-8. PubMed ID: 17984937
[TBL] [Abstract][Full Text] [Related]
37. [Effect of gestrinone on the lipid metabolic parameters and bone mineral density in patients with endometriosis].
Zheng P; Zhang YF; Wang JD
Zhonghua Fu Chan Ke Za Zhi; 2005 Mar; 40(3):175-7. PubMed ID: 15840312
[TBL] [Abstract][Full Text] [Related]
38. The effect of sexual hormone abnormalities on proximal femur bone mineral density in hemodialysis patients and the possible role of RANKL.
Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Grapsa EI; Passalidou IA; Tziamalis MP; Poulakou MV; Vlachos IS; Perrea DN
Hemodial Int; 2008 Jan; 12(1):100-7. PubMed ID: 18271850
[TBL] [Abstract][Full Text] [Related]
39. The impact of serum FSH and estradiol on postmenopausal osteoporosis related to time since menopause.
Yoldemir T; Erenus M; Durmusoglu F
Gynecol Endocrinol; 2012 Nov; 28(11):884-8. PubMed ID: 22731753
[TBL] [Abstract][Full Text] [Related]
40. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
Greenwald MW; Gluck OS; Lang E; Rakov V
Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
